TickerFiles

Acrivon Therapeutics, Inc. 10-Q filing

Filed 2025-08-13 · Report date 2025-06-30 · 2025

View Original SEC Filing

Filing metadata

Accession number
0000950170-25-108054
Form type
10-Q
CIK
0001781174
Primary document
https://www.sec.gov/Archives/edgar/data/1781174/000095017025108054/acrv-20250630.htm

Extracted primary information

This filing includes deterministic financial metrics extracted from public filing data for Acrivon Therapeutics, Inc..

Reported financial metrics

MetricCurrentPriorChange
Operating Income$-44.3M--
Net Income$-40.7M--
Eps Basic-1.06--
Eps Diluted-1.06--
Cash And Equivalents$41.9M--
Total Assets$158.6M--
Total Liabilities$15.5M--
Shareholders Equity$143.0M--
Operating Cash Flow$-36.1M--
Capital Expenditures$551,000--